A phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions
Sponsor: |
IDEAYA Biosciences |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS4168 |
U.S. Govt. ID: |
NCT03947385 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to evaluate the safety profile of IDE196 (an investigational drug), in enrolled subjects to find out if it is safe and possibly helpful in patients with certain cancers such as metastatic uveal melanoma, cervical cancer, lung cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, cutaneous melanoma or colorectal cancer or cancers with mutations in genes called GNAQ, GNA11, or PRKC fusion. The study may last for approximately 25 months and your participation will depend on how well you tolerate the study drug and your overall condition during the study.
Investigator
Alexander Wei, MD
Are you 18 years of age or older? |
Yes |
No |
Do you have a solid tumor(s) that has either progressed following prior standard therapies? |
Yes |
No |
Are you willing to possibly undergo biopsies during the study? |
Yes |
No |